Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries

References

• C. Choudhary, C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, and M. Mann, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science 325 (2009), pp. 834–840.
   PubMed Web of Science ®Google Scholar
• K.J. Falkenberg and R.W. Johnstone, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, Nat. Rev. Drug Discov. 13 (2014), pp. 673–691.
   PubMed Web of Science ®Google Scholar
• X.-J. Yang and E. Seto, The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men, Nat. Rev. Mol. Cell. Biol. 9 (2008), pp. 206–218.
   PubMed Web of Science ®Google Scholar
• L. Zhang, Y. Han, Q. Jiang, C. Wang, X. Chen, X. Li, F. Xu, Y. Jiang, Q. Wang, and W. Xu, Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy, Med. Res. Rev. 35 (2015), pp. 63–84.
   PubMed Web of Science ®Google Scholar
• P. Ma and R.M. Schultz, Histone deacetylase 2 (HDAC2) regulates chromosome segregation and kinetochore function via H4K16 deacetylation during oocyte maturation in mouse, PLoS Genet. 9 (2013), p. e1003377.
   PubMed Web of Science ®Google Scholar
• M.F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N.G. Iyer, A. Perez-Rosado, E. Calvo, J.A. Lopez, A. Cano, M.J. Calasanz, D. Colomer, M.A. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein, and M. Esteller, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nat. Genet. 37 (2005), pp. 391–400.
   PubMed Web of Science ®Google Scholar
• K.M. Miller, J.V. Tjeertes, J. Coates, G. Legube, S.E. Polo, S. Britton, and S.P. Jackson, Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining, Nat. Struct. Mol. Biol. 17 (2010), pp. 1144–1151.
   PubMed Web of Science ®Google Scholar
• M. Mottamal, S. Zheng, L.T. Huang, and G. Wang, Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules 20 (2015), pp. 3898–3941.
   PubMed Web of Science ®Google Scholar
• E. Pontiki and D. Hadjipavlou-Litina, Histone deacetylase inhibitors (HDACIs). Structure–activity relationships: History and new QSAR perspectives, Med. Res. Rev. 32 (2012), pp. 1–165.
   PubMed Web of Science ®Google Scholar
• X. Aihua, L. Chenzhong, L. Zhibin, N. Zhiqiang, H. Weiming, L. Xianping, S. Leming, and Z. Jiaju, Quantitative structure-activity relationship study of histone deacetylase inhibitors, Curr. Med. Chem. Anticancer Agents 4 (2004), pp. 273–299.
   PubMedGoogle Scholar
• D.-F. Wang, O. Wiest, P. Helquist, H.-Y. Lan-Hargest, and N.L. Wiech, QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids, Bioorg. Med. Chem. Lett. 14 (2004), pp. 707–711.
   PubMed Web of Science ®Google Scholar
• Y. Guo, J. Xiao, Z. Guo, F. Chu, Y. Cheng, and S. Wu, Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses, Bioorg. Med. Chem. 13 (2005), pp. 5424–5434.
   PubMed Web of Science ®Google Scholar
• N.K. Wagh, H.S. Deokar, D.C. Juvale, S.S. Kadam, and V.M. Kulkarni, 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation, Indian J. Biochem. Biophys. 43 (2006), pp. 360–371.
   PubMed Web of Science ®Google Scholar
• D.C. Juvale, V.V. Kulkarni, H.S. Deokar, N.K. Wagh, S.B. Padhye, and V.M. Kulkarni, 3D-QSAR of histone deacetylase inhibitors: Hydroxamate analogues, Org. Biomol. Chem. 4 (2006), pp. 2858–2868.
   PubMed Web of Science ®Google Scholar
• R. Ragno, S. Simeoni, S. Valente, S. Massa, and A. Mai, 3-D QSAR Studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds, J. Chem. Inf. Model. 46 (2006), pp. 1420–1430.
   PubMed Web of Science ®Google Scholar
• A.R. Katritzky, S.H. Slavov, D.A. Dobchev, and M. Karelson, Comparison between 2D and 3D-QSAR approaches to correlate inhibitor activity for a series of indole amide hydroxamic acids, QSAR Comb. Sci. 26 (2007), pp. 333–345.
   Google Scholar
• N. Dessalew, QSAR study on aminophenylbenzamides and acrylamides as histone deacetylase inhibitors: An insight into the structural basis of antiproliferative activity, Med. Chem. Res. 16 (2007), pp. 449–460.
   Web of Science ®Google Scholar
• R. Ragno, S. Simeoni, D. Rotili, A. Caroli, G. Botta, G. Brosch, S. Massa, and A. Mai, Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies, Eur. J. Med. Chem. 43 (2008), pp. 621–632.
   PubMed Web of Science ®Google Scholar
• A.P. Kozikowski, Y. Chen, A.M. Gaysin, D.N. Savoy, D.D. Billadeau, and K.H. Kim, Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors – Nanomolar-potency inhibitors of pancreatic cancer cell growth, ChemMedChem 3 (2008), pp. 487–501.
   PubMed Web of Science ®Google Scholar
• Y.-D. Chen, Y.-J. Jiang, J.-W. Zhou, Q.-S. Yu, and Q.-D. You, Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling, J. Mol. Graph. Model. 26 (2008), pp. 1160–1168.
   PubMed Web of Science ®Google Scholar
• Y. Chen, H. Li, W. Tang, C. Zhu, Y. Jiang, J. Zou, Q. Yu, and Q. You, 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment, Eur. J. Med. Chem. 44 (2009), pp. 2868–2876.
   PubMed Web of Science ®Google Scholar
• G. Melagraki, A. Afantitis, H. Sarimveis, P.A. Koutentis, G. Kollias, and O. Igglessi-Markopoulou, Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors, Mol. Divers. 13 (2009), pp. 301–311.
   PubMed Web of Science ®Google Scholar
• H. Tang, X.S. Wang, X.-P. Huang, B.L. Roth, K.V. Butler, A.P. Kozikowski, M. Jung, and A. Tropsha, Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation, J. Chem. Inf. Model. 49 (2009), pp. 461–476.
   PubMed Web of Science ®Google Scholar
• X.H. Liu, H.Y. Song, J.X. Zhang, B.C. Han, X.N. Wei, X.H. Ma, W.K. Cui, and Y.Z. Chen, Identifying novel type ZBGs and nonhydroxamate HDAC inhibitors through a SVM based virtual screening approach, Mol. Inf. 29 (2010), pp. 407–420.
   PubMed Web of Science ®Google Scholar
• A. Beheshti, E. Pourbasheer, M. Nekoei, and A. Banaei, Quantitative structure-activity relationship study of amino acid derivatives as histone deacetylase inhibitors using the genetic algorithm – Multiple linear regression, Anal. Chem. Lett. 2 (2012), pp. 33–43.
   Google Scholar
• J.-S. Yang, T.-G. Chun, K.-Y. Nam, H.-M. Kim, and G.-H. Han, Structure-activity relationship of novel lactam based histone deacetylase inhibitors as potential anticancer drugs, Bull. Korean Chem. Soc. 33 (2012), pp. 2063–2066.
   Web of Science ®Google Scholar
• S.B. Nair, M.K. Teli, H. Pradeep, and G.K. Rajanikant, Computational identification of novel histone deacetylase inhibitors by docking based QSAR, Comput. Biol. Med. 42 (2012), pp. 697–705.
   PubMed Web of Science ®Google Scholar
• Y. Xiang, Z. Hou, and Z. Zhang, Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors, Chem. Biol. Drug Des. 79 (2012), pp. 760–770.
   PubMed Web of Science ®Google Scholar
• L. Zhao, Y. Xiang, J. Song, and Z. Zhang, A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors, Bioorg. Med. Chem. Lett. 23 (2013), pp. 929–933.
   PubMed Web of Science ®Google Scholar
• G.P. Cao, M. Arooj, S. Thangapandian, C. Park, V. Arulalapperumal, Y. Kim, Y.J. Kwon, H.H. Kim, J.K. Suh, and K.W. Lee, A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors, SAR QSAR Environ. Res. 26 (2015), pp. 397–420.
   PubMed Web of Science ®Google Scholar
• Z. Noor, N. Afzal, and S. Rashid, Exploration of novel inhibitors for class I histone deacetylase isoforms by QSAR modeling and molecular dynamics simulation assays, PLOS ONE 10 (2015), p. e0139588.
   Google Scholar
• Y. Bi, Z. Liu, X. Liu, X. Zhang, and J. Lu, Molecular docking and 3D-QSAR studies on quinolone-based HDAC inhibitors, Lett. Drug Des. Discov. 13 (2016), pp. 577–586.
   Web of Science ®Google Scholar
• S. Sinha, S. Goyal, P. Somvanshi, and A. Grover, Mechanistic insights into the binding of class IIa HDAC inhibitors toward spinocerebellar ataxia type-2: A 3D-QSAR and pharmacophore modeling approach, Front. Neurosci. 10 (2017), p. 606.
   PubMed Web of Science ®Google Scholar
• H. Tang, X.S. Wang, X.P. Huang, B.L. Roth, K.V. Butler, A.P. Kozikowski, M. Jung, and A. Tropsha, Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation, J. Chem. Inf. Model. 49 (2009), pp. 461–76.
   PubMed Web of Science ®Google Scholar
• Z. Noor, N. Afzal, and S. Rashid, Exploration of novel inhibitors for class I histone deacetylase isoforms by QSAR modeling and molecular dynamics simulation assays, PLOS ONE. 10 (2015), p. e0139588.
   Google Scholar
• A. Lavecchia, Machine-learning approaches in drug discovery: Methods and applications, Drug Discov. Today 20 (2015), pp. 318–331.
   PubMed Web of Science ®Google Scholar
• H. Le-Thi-Thu, G.M. Casanola-Martín, Y. Marrero-Ponce, A. Rescigno, C. Abad, and M.T. Khan, A rational workflow for sequential virtual screening of chemical libraries on searching for new tyrosinase inhibitors, Curr. Top. Med. Chem. 14 (2014), pp. 1473–1485.
   PubMed Web of Science ®Google Scholar
• D.T.K. Oanh, H.V. Hai, S.H. Park, H.-J. Kim, B.-W. Han, H.-S. Kim, J.-T. Hong, S.-B. Han, V.T.M. Hue, and N.-H. Nam, Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents, Bioorg. Med. Chem. Lett. 21 (2011), pp. 7509–7512.
   PubMed Web of Science ®Google Scholar
• T. Tung, O.D.T. Kim, and D.P.T. Phuong, H. VT, P. SH, H.B. Woo, K. Y, H. JT, H. Sang-Bae, and N. Nguyen-Hai, New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents, Med. Chem. 9 (2013), pp. 1051–1057.
   PubMed Web of Science ®Google Scholar
• N.-H. Nam, T.L. Huong, and D.T. Mai, Dung, P.T. Phuong Dung, D.T. Kim Oanh, D. Quyen, L.T. Thao, S.H. Park, K.R. Kim, B.W. Han, J. Yun, J.S. Kang, Y. Kim, and S.-B. Han, Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents, Eur. J. Med. Chem. 70 (2013), pp. 477–486.
   PubMed Web of Science ®Google Scholar
• N. Nguyen-Hai, H.T. Lan, D.D.T. Mai, D.P.T. Phuong, O.D.T. Kim, P.S. Ho, K. Kyungrok, H.B. Woo, Y. Jieun, K.J. Soon, K. Youngsoo, and H. Sang-Bae, Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents, J. Enzyme Inhib. Med. Chem. 29 (2014), pp. 611–618.
   PubMed Web of Science ®Google Scholar
• Do T.M. Dung, PTP Dung, DTK Oanh, H. Pham-The, H. Le-Thi-Thu, L. Vu-Duc, H. Hahn, B.W. Han, J. Kim, S.B. Han, and N. Nguyen-Hai, Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents, Med. Chem. 11 (2015), pp. 725–735.
   PubMed Web of Science ®Google Scholar
• H.T.T. Lan, D.D.T. Mai, D.P.T. Phuong, H.P. Thanh, V.T. Khac, H. Hyunggu, H.B. Woo, K. Jisung, P. Minji, H. Sang-Bae, and N. Nguyen-Hai, Novel 2-oxoindoline-based hydroxamic acids: Synthesis, cytotoxicity, and inhibition of histone deacetylation, Tetrahedron Lett. 56 (2015), pp. 6425–6429.
   Web of Science ®Google Scholar
• R.Z. Cer, U. Mudunuri, R. Stephens, and F.J. Lebeda, IC50-to-Ki: A web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding, Nucleic Acids Res. 37 (2009), pp. W441–W445.
   PubMed Web of Science ®Google Scholar
• G.M. Keseru and G.M. Makara, The influence of lead discovery strategies on the properties of drug candidates, Nat. Rev. Drug Discov. 8 (2009), pp. 203–212.
   PubMed Web of Science ®Google Scholar
• Murugan K, Sangeetha S, Ranjitha S, Vimala A, Al-Sohaibani S, and R. G, HDACiDB: A database for histone deacetylase inhibitors, Drug Des. Devel. Ther. 9 (2015), pp. 2257-2264.
   Google Scholar
• N. Mills, ChemDraw Ultra 10.0 CambridgeSoft, 100 Cambridge Park Drive, Cambridge, MA 02140. www.cambridgesoft.com. Commercial Price: $1910 for download, $2150 for CD-ROM; Academic Price: $710 for download, $800 for CD-ROM, J. Am. Chem. Soc. 128 (2006), pp. 13649–13650.
   Web of Science ®Google Scholar
• DRAGON for Windows (Software for Molecular Descriptor Calculator), Version 6.0. Talete srl, Milano Chemometrics and QSAR Research Group, (http://www.talete.mi.it/), 2011.
   Google Scholar
• HyperChem (TM) Professional, Version 8.0.5, Hypercube, Inc. Florida, USA, (www.hyper.com), 2008.
   Google Scholar
• STATISTICA (data analysis software system), Version 8.0.1, StatSoft, Inc., Tulsa, OK, (www.statsoft.com), 2012.
   Google Scholar
• H. Pham-The, I. Gonzalez Diaz, M. Bermejo Sanz, V. Mangas Sanjuan, I. Centelles, T.M. Garriges, and M.A. Cabrera-Perez, In silico prediction of Caco-2 permeability by a classification QSAR approach, Mol. Inf. 30 (2011), pp. 376-385.
   Google Scholar
• H.I. Witten, and E. Frank, Data Mining: Practical Machine Learning Tools and Techniques, Morgan Kaufmann (MK) Publisher, San Francisco, USA, 2005.
   Google Scholar
• L. Huma and Y. Yoshihiro, Chemoinformatics and Advanced Machine Learning Perspectives: Complex Computational Methods and Collaborative Techniques, IGI Global, Hershey, PA, USA, 2011.
   Google Scholar
• A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, and V. Consonni, V.E. Kuz’min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard, and A. Tropsha, QSAR modeling: Where have you been? Where are you going to?, J. Med. Chem. 57 (2014), pp. 4977–5010.
   PubMed Web of Science ®Google Scholar
• OECD, Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships [(Q)SAR] Models, in OECD Series on Testing and Assessment No. 69. ENV/JM/MONO(2007)2, Organisation for Economic Cooperation and Development, Paris, France, 2007, pp. 154.
   Google Scholar
• T. Alexander and G. Alexander, Predictive quantitative structure-activity relationships modeling, in Handbook of Chemoinformatics Algorithms, J.L. Faulon and A. Bender, eds., Chapman and Hall/CRC, New York, USA, 2010, pp. 173–210.
   Google Scholar
• K.K. Chohan, S.W. Paine, J. Mistry, P. Barton, and A.M. Davis, A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries, J. Med. Chem. 48 (2005), pp. 5154–5161.
   PubMed Web of Science ®Google Scholar
• F. Provost and T. Fawcett, Analysis and visualization of classifier performance: comparison under imprecise class and cost distribution, in Third International Conference on Knowledge Discovery and Data Mining (KDD-97), J. W. Shavlik, ed., Menlo Park, CA: AAAI Press, Newport Beach, California, 1997, pp. 43-48.
   Google Scholar
• J.A. Hanley and B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve, Radiology 143 (1982), pp. 29–36.
   PubMed Web of Science ®Google Scholar
• R.M. O’Brien, A caution regarding rules of thumb for variance inflation factors, Qual. Quant. 41 (2007), pp. 673–690.
   Web of Science ®Google Scholar
• S.C. Peterangelo and P.G. Seybold, Synergistic interactions among QSAR descriptors, Int. J. Quantum Chem. 96 (2004), pp. 1–9.
   Web of Science ®Google Scholar
• Jason D. M. Rennie, L. Shih, J. Teevan, and D.R. Karger, Tackling the poor assumptions of Naive Bayes text classifiers, Proceedings of the Twentieth International Conference on Machine Learning (ICML) 20 (2003), pp. 616-623.
   Google Scholar
• C. Wang, L.M. Henkes, L.B. Doughty, M. He, D. Wang, F.-J. Meyer-Almes, and Y.-Q. Cheng, Thailandepsins: Bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities, J. Nat. Prod. 74 (2011), pp. 2031–2038.
   PubMed Web of Science ®Google Scholar
• R. Todeschini, and V. Consonni, Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References, Vol. 41, Wiley VCH, Weinheim, Germany, 2010.
   Google Scholar
• D. Hadjipavlou-Litina and E. Pontiki, Quantitative structure–activity relationship studies on hydroxamic acids acting as histone deacetylase inhibitors, in Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities, P.S. Gupta, ed., Springer, Berlin Heidelberg, Berlin, Heidelberg, 2013, pp. 205–240.
   Google Scholar
• C. Salmi-Smail, A. Fabre, F. Dequiedt, A. Restouin, R. Castellano, S. Garbit, P. Roche, X. Morelli, J.M. Brunel, and Y. Collette, Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity, J. Med. Chem. 53 (2010), pp. 3038–3047.
   PubMed Web of Science ®Google Scholar
• J.C. Bressi, A.J. Jennings, R. Skene, Y. Wu, R. Melkus, R.D. Jong, S. O’Connell, C.E. Grimshaw, M. Navre, and A.R. Gangloff, Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3142–3145.
   PubMed Web of Science ®Google Scholar
• R.R. Frey, C.K. Wada, R.B. Garland, M.L. Curtin, M.R. Michaelides, J. Li, L.J. Pease, K.B. Glaser, P.A. Marcotte, J.J. Bouska, S.S. Murphy, and S.K. Davidsen, Trifluoromethyl ketones as inhibitors of histone deacetylase, Bioorg. Med. Chem. Lett. 12 (2002), pp. 3443–3447.
   PubMed Web of Science ®Google Scholar
• G. Derringer and R. Suich, Simultaneous optimization of several response variables, J. Qual. Technol. 12 (1980), pp. 214–219.
   Web of Science ®Google Scholar
• A.V. Bieliauskas and M.K.H. Pflum, Isoform-selective histone deacetylase inhibitors, Chem. Soc. Rev. 37 (2008), pp. 1402–1413.
   PubMed Web of Science ®Google Scholar
• P.K. Alan and V.B. Kyle, Chemical origins of isoform selectivity in histone deacetylase inhibitors, Curr. Pharm. Des. 14 (2008), pp. 505–528.
   PubMed Web of Science ®Google Scholar
• F. Thaler and C. Mercurio, Towards selective inhibition of histone deacetylase isoforms: What has been achieved, where we are and what will be next?, ChemMedChem 9 (2014), pp. 523–536.
   PubMed Web of Science ®Google Scholar